🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#SGBCC2025 How to treat patients with stage II ER+ breast cancer, depending on nodal status and OncotypeDX score:

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by Harold J. Burstein, MD, PhD, FASCO & G Curigliano MD PhD. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

⁦FDA⁩ approves pembrolizumab + trastuzumab + chemo for 1L treatment of metastatic HER2+ gastric cancer (PD-L1 CPS ≥1). ✅ PFS: 10.9 vs. 7.3 mo (HR: 0.72) ✅ OS: 20.1 vs. 15.7 mo (HR: 0.79) ✅ ORR: 73% vs. 58% #Oncology ⁦⁦⁦OncoAlert fda.gov/drugs/resource…

Just published in Journal of Clinical Oncology the updated ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues OncoAlert Ann Partridge MD, MPH Oncofertility Link: ascopubs.org/doi/10.1200/JC…

Falchook et al. #review a new #clinicaltrial "Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials" doi.org/10.36401/JIPO-… #CDK2 #clinicaltrial #JIPO Innovative Oncology Network

1/ Excited to share our new paper in npj Digital Medicine. We worked with Fei Wang to develop a cutting-edge AI model 🖥️ that predicts response to neoadjuvant chemotherapy 💉 in patients with muscle-invasive #bladdercancer in the S1314 randomized clinical trial

🚨 ESMO’s New Global Guidelines for Molecular Tumor Boards (MTBs) 🧬💻 Published in Annals of Oncology, this comprehensive special article by Ben Westphalen et al. and the ESMO - Eur. Oncology Precision Oncology Working Group delivers international recommendations to standardize MTB

🧩 ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at Weill Cornell Medicine Excited to share collaborative paper #2 this month. This time with the brilliant Alexandre Pellan Cheng & Dan Landau! rdcu.be/ehkUb Nature Methods Highlights: 🔬

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer buff.ly/DKNZAFk The phase III CodeBreaK 300 trial demonstrated that sotorasib 960 mg combined with

Falchook et al. summarize past and current CDK2 inhibitors in clinical trials in this #JIPO review doi.org/10.36401/JIPO-… #CDK2 #clinicaltrial #JIPO Innovative Oncology Network

🚨 cfRNA is Here — and It’s a Game Changer! 🧬🩸 Max Diehn, MD/PhD et al., nature 2025 🔗 DOI: 10.1038/s41586-025-08834-1 👏 From one of our #ISLB awardees! 🔍 Key Highlights: ✅ RAREseq: A new method for ultrasensitive cfRNA profiling 💡 ✅ cfRNA detects early-stage NSCLC with

🆕article in press: Copenhagen Prospective Personalized Oncology (CoPPO) – Impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting doi.org/10.1016/j.anno…

🎤 Aiming to cure cancer? Start systemic therapy early! I am excited to present the interim results of our investigator-initiated trial Weill Cornell Medicine Weill Cornell Medicine Meyer Cancer Center, Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer (CLONEVO) #BladderCancer AACR #AACR25

The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell #LungCancer in a phase I clinical trial, according to results presented by Kathryn C. Arbour, MD: aacr.org/about-the-aacr… #AACR25 Kathryn C. Arbour Memorial Sloan Kettering Cancer Center

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrE

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

Very promising data with KAT6 inhibition + fulvestrant presented by Pat LoRusso. Among 43 pts with HR+/HER2- MBC, all with prior CDK4/6i, ORR was 37%, mPFS 10.7 months. Main toxicity: 74% with dysgeusia (paging Antonio Giordano, MD PhD for the pronunciation of this tox). #ASCO25

Excellent #ASCO25 infographic highlighting the results of the DESTINY-Breast09 study: 👉Participants in the #TDXd + #Pertuzumab arm lived longer without their disease growing, spreading, or getting worse compared with participants in the THP (taxane + trastuzumab + pertuzumab)

Sheshadri et al. comments on recent case report "Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer" doi.org/10.36401/JIPO-… #JIPO #NSCLC #Pneumonitis Ajay Sheshadri

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator | Cancer Discovery | American Association for Cancer Research aacrjournals.org/cancerdiscover…